Megan Browdie

Megan solves clients’ antitrust issues, guiding transactions through merger review and representing clients in government investigations and litigation. She regularly counsels clients – including private equity sponsors – on a variety of topics, including pricing practices, licensing of intellectual property and other distribution issues. Megan has helped to secure critical wins for clients in a number of cases and has experience in matters before the Department of Justice, Federal Trade Commission and state antitrust authorities.

Chambers USA, Super Lawyers, Best Lawyers and Who’s Who Legal recognize Megan as a top antitrust practitioner. Chambers quotes clients describing Megan as “an expert” who is “great to work with.” 

Megan works with clients in a variety of industries, including automotive, consumer goods, computer hardware, financial services, Internet of Things, oil and gas, pharmaceuticals and medical devices, publishing, software and telecommunications.

Megan also is an active member of the American Bar Association’s Antitrust Law Section. She is currently a vice chair on the Health Care and Pharmaceuticals Committee and previously served in various positions on the M&A Committee, the Federal Civil Enforcement Committee and the Presidential Transition Task Force. Megan was also as an editor for Antitrust Law Developments (Ninth Edition), the premier antitrust treatise. 

Megan maintains a vibrant pro bono practice, typically representing caregivers and children in the Washington, DC area. Megan is also co-chair of Cooley’s DC Pro Bono Committee.

Megan’s representative matters include:

• Representation of Gracell Biotechnologies in its $1.2 billion sale to AstraZeneca
• Representation of Stratasys, a top 3D printer manufacturer, in multiple acquisitions, including the 2023 acquisition of Desktop Metal, the 2022 merger of its subsidiary MakerBot with Ultimaker, and earlier acquisitions of MakerBot, Solid Concepts and Harvest Technologies, and Objet Ltd. in its merger with Stratasys, Inc. to form Stratasys
• Representation of One Medical in its $3.9 billion sale to Amazon, a transaction closing without remedies after an extensive investigation; Megan previously represented One Medical in its $2.1 billion acquisition of Iora Health to expand its member-based, technology-powered primary care model to every stage of life
• Representation of Apollo Endosurgery, a medical device company, in its $615 million sale to Boston Scientific, expanding Boston Scientific’s global capabilities in endoluminal surgery procedures
• Representation of Tmunity Therapeutics, a biotech company focused on next-generation CAR-T cell therapies and technologies, in its sale to Kite/Gilead, completing Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets and a rapid manufacturing process
• Representation of TCGPlayer, an online marketplace for trading card games, in its $295 million sale to eBay
• Representation of Zoom in multiple acquisitions, including its $15.7 billion acquisition of Five9 (later abandoned) and its acquisition of Solvvy to expand its contact center offerings
• Representation of Prasco as the divestiture buyer of generic drugs to resolve FTC issues raised by the combination of Pfizer Upjohn and Mylan to form Viatris
• Representation of Sazerac in multiple acquisitions, including from Constellation Brands (as the divestiture buyer for Paul Masson Brandy Grande Amber), Brown-Forman (Early Times, Canadian Mist, Southern Comfort and other brands) and Diageo (Seagram’s VO and other brands)
• Representation of Vividion Therapeutics in its up to $2 billion sale to Bayer AG
• Representation of Cornerstone OnDemand, a global leader in people development solutions, in its acquisition of talent experience solutions competitor Saba Software for $1.3 billion
• Representation of TiVo in its $3 billion merger with Xperi, creating a top consumer and entertainment technology business and one of the industry’s largest intellectual property licensing platforms and also obtaining unconditional clearance in the US and Korea
• Representation of Forty Seven in its sale to Gilead for $4.9 billion, strengthening Gilead’s immuno-oncology research and development portfolio
• Representation of Tableau in its $15.7 billion acquisition by Salesforce, combining the world’s #1 customer relationship management (CRM) system and #1 analytics platform
• Representation of ZOLL Medical, a manufacturer of medical devices, in its acquisition of Cardiac Science Corporation, combining two top manufacturers of automated external defibrillators (AEDs), allowing the firm to place lifesaving technology into the hands of more lay rescuers and first responders during medical emergencies
• Representation of Abaxis, a top provider of veterinary point-of-care diagnostic instruments, in its $2 billion acquisition by Zoetis, a top animal health company with a competitive business, winning unconditional clearance from the FTC and the German competition authority
• Representation of minuteKEY, the top supplier of self-service key duplication kiosks, in its sale to Hillman, the top supplier of back-of-store key-cutting equipment, cleared by the FTC after an intense review
• Representation of BroadSoft Corporation, a top unified communications as a service (UCaaS) provider, in its $1.9 billion acquisition by Cisco Systems, a rival UCaaS provider
• Representation of iCardiac Technologies in its acquisition by ERT, expanding ERT’s portfolio of centralized cardiac safety and respiratory laboratory solutions
• Representation of ZELTIQ Aesthetics, a top medical technology company whose flagship CoolSculpting system is the sales leader in the body contouring segment of medical aesthetics, in its $2.4 billion acquisition by biopharmaceutical manufacturer Allergan, expanding Allergan’s global aesthetic business
• Representation of com Holdings, Inc. in its acquisition of the Connect and Piper business units from Icontrol Networks in a transaction that closed without divestitures or restructuring after an eight-month FTC investigation; Megan also successfully defended the company in private litigation seeking to block the merger in the US District Court for the District of New Jersey
• Defense of the Eastman Kodak Company against allegations of illegal tying and monopolization in Collins v. Kodak, which settled on confidential terms; Megan also was on the team that successfully argued for a new standard for implicit (i.e., noncontractual) tying in the US Court of Appeals for the Sixth Circuit

Recent speaking engagements

• Panelist, “Healthcare & Pharmaceuticals Committee: Recent Developments, Q2 2023,” American Bar Association, July 2023
• Panelist, “Examining Emerging Competition Issues Involving Digital Health and Virtual Healthcare,” American Bar Association, May 2023
• Panelist, “Antitrust Enforcement in the Biden Administration: The Rhetoric, the Record, and Future Priorities,” Practising Law Institute (PLI) program, September 2022
• Speaker, “Innovation, IP, and Antitrust Tools Reconsidered,” The George Washington University and Information Technology and Innovation Foundation (ITIF) Joint Conference on Dynamic Competition and Public Policy, April 2022
• Faculty, “Introduction to Antitrust,” Federal Communications Bar Association (FCBA) Diversity Pipeline Program, March 2022
• Panelist, “Life Sciences in the Antitrust Hot Seat – Trends and Guidance,” Cooley Life Sciences & Healthcare Innovation Program, January 2022
• Faculty, “Interactions With Competitors: Collaboration and Exclusion,” PLI Antitrust Counseling & Compliance program, 2020 – 2022
• Moderator, “Deal or No Deal? Lessons From Recent Merger Decisions,” American Bar Association (ABA) Antitrust Law Section webinar, May 2020
• Panelist, “Antitrust Enforcement in the Time of COVID-19: What You Need to Know,” PLI program, April 2020
• Panelist, “US Merger Control in 2020: What You Need to Know,” Lexology webinar, January 2020
• Panelist, “Recent Developments in Health Care and Pharmaceuticals Q4 2019,” ABA Antitrust Law Section webinar, January 2020
• Moderator, “The Fundamentals of Pricing,” ABA Antitrust Law Section webinar, November 2019
• Panelist, “The 2020 Candidates’ Views on Competition and Antitrust,” ABA Antitrust Law Section webinar, November 2019
• Panelist, “Antitrust and High-Tech in the Spotlight: What Does It All Mean?,” PLI program, September 2019
• Panelist, “Antitrust in 2019: Trends and Developments to Watch,” PLI program, January 2019
• Panelist, “ v. AT&T-Time Warner: Implications for Future Antitrust Merger Enforcement,” PLI program, June 2018
• Panelist, “Monthly Antitrust Update for In-House Counsel,” ABA Antitrust Law Section webinar, March 2018
• Moderator, “Nuts & Bolts of Premerger Conduct: Where’s the Line in the Sand?,” ABA Antitrust Law Section webinar, January 2018

Recent publications

• Editor, Antitrust Law Developments (Ninth Edition), 2022
• Co-author, “Biden/Harris Expected to Double Down on Antitrust Enforcement: No Trump Card in the Deck,” Concurrences, January 2021 
• Co-author, “United States: Technology Mergers,” Global Competition Review, September 2019